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Summary The effects of cimetidine and indomethacin on the growth of dimethylhydrazine induced or
transplanted intestinal tumours in the rat have been studied. Cimetidine is a histamine type 2 receptor
antagonist and indomethacin is an inhibitor of prostaglandin synthesis. Two models of rat intestinal tumours
were used: a colon carcinoma line transplantable in syngeneic animals and intestinal tumours induced by
dimethylhydrazine treatment of Sprague-Dawley rats. Cimetidine and indomethacin were given in drinking
water, alone or in combination. Cimetidine had no effect on the growth of transplanted colon cancer but
significantly increased the incidence of chemically-induced tumours, with a tendency toward more invasive
and metastatic tumours than in the control animals. Indomethacin did not significantly modify the incidence
or other characteristics of the tumours in any of the models. This result is at variance with a protective effect
of indomethacin on chemically-induced rat colon cancer previously reported by others.
In spite of numerous attempts, treatment of
advanced or residual colorectal cancer by cytotoxic
agents can be considered a failure. Since surgery is
efficient only in the early forms of disease, other
methods of treatment need to be found. Two
groups have recently reported that indomethacin, a
potent inhibitor of prostaglandin synthesis, was
able to inhibit the growth of intestinal tumours
indiced by a,variety of carcinogenec agents in the
rat (Pollard & Luckert, 1980; Kudo et al., 1980). It
has also been reported that cimetidine, a histamine
type-2 receptor antagonist widely used in the
treatment of peptic ulcer, could inhibit the growth
of experimental tumours in rodents. This could
perhaps occur through its blocking effect on
histamine H-2 receptors at the surface of suppressor
T lymphocytes (Gifford et al., 1981; Osband et al.,
1981).
Because indomethacin and cimetidine could have
a cooperative effect on tumour growth, the
efficiency of both drugs was tested individually or
in combination, on experimental intestinal cancer.
Two models were used in this work: a colon
carcinoma line transplantable in syngeneic BDIX
strain rats and intestinal tunours induced by
dimethylhydrazine in Sprague-Dawley rats.
Materials and methods
Animals
Two strains of syngeneic rats were used in this
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work: BDIX rats, bred in our laboratory by
brother-sister mating, and Sprague-Dawley rats
(IFFA-Credo, L'Arbresle, France). They were kept
in an air-conditioned, humidity-controlled room,
with a Light-dark cycle of 12h. They were allowed
drinking water ad libidum and fed Extralabo
biscuits (Sainte-Colombe, France). To determine
the lipidic composition of the biscuits, lipids were
extracted according to Folch et al., (1957) and the
fatty acids were analyzed by gas-liquid
chromatography as their methyl ester derivatives.
The mean fatty acid content was 4.3% of the
biscuit weight, unsaturated fatty acids and linoleic
acid being respectively 60% and 21% of the total
fatty acids.
Transplantable colonic tumours
Tumour DHD is a transplantable well
differentiated carcinoma originating in a colonic
tumour induced by 1,2 dimethylhydrazine in a
BDIX rat (Martin et al., 1973). It was maintained
by s.c. implantation in syngeneic rats. A tumour at
the 16th passage was used in this work. A tumour
fragment, - 50mg, was implanted s.c. in the
anterior thoracic wall of 60 BDIX rats. Animals
were randomly allocated to the experimental
groups; treatment by indomethacin and/or
cimetidine was begun on the day of the graft. Rats
were examined weekly and the tumour was
measured with a calliper in 2 perpendicular
dimensions. Tumour volume was estimated by the
product of half the length by the square of the
width. All the animals were sacrificed 49 days after
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tumour implantation. The s.c. tumours were
carefully excised and weighed.
Chemically induced colonic tumours
Weanling conventional male Sprague-Dawley rats
were given five doses of 1,2 dimethylhydrazine
(Merck, Darmstadt, Germany) by gavage, one a
week, at a dose of 30mgkg-1 body wt. The drug
was freshly dissolved in saline prior to
administration. Animals were randomly allocated to
experimental groups and the treatment by
indomethacin and/or cimetidine was begun 4 days
after the last administration of dimethylhydrazine.
Six months after the beginning of the treatment, all
the rats were killed by deep ether anaesthesia, the
gastrointestinal tract was excised, opened and
carefully examined for number and location of
lesions. Metastases to lymph nodes, peritoneal
cavities and lung were systematically sought. The
tissues were fixed in Bouin's solution and processed
for histological examination. The results with
individual rats per group were analyzed statistically
by the Mann-Whitney test.
Administration ofthe drugs
Indomethacin (Sigma, St Louis, USA) and
cimetidine (a gift of Smith, Kline and French,
Welwyn Garden, UK) were given in the drinking
water at concentrations of 20 mg 1- for
indomethacin and 500mgml-1 for cimetidine. We
selected the same doses of indomethacin that
Pollard & Luckert (1980) had previously used for
treating rat colon cancer. The doses of cimetidine
were chosen in approximate correspondence to
these used by Gifford et al. (1981) to suppress
the growth of a methylcholanthrene-induced
fibrosarcoma in mice. Indomethacin was dissolved
in a small amount of absolute ethanol which was
then added to tap water. Fresh drug solutions were
prepared twice a week. It was shown that the mean
daily consumption of drinking water was
- 200ml-1 body wt. In the experiments with
transplanted or chemically-induced intestinal
tumours, rats were allocated to 4 experimental
groups: one group received cimetidine, one group
indomethacin, one group cimetidine plus
indomethacin and one group drinking water
without drug. Drug administration was continued
up to the killing of the animals.
Results
Transplanted intestinal tumours
No significant differences were observed between
control and treated animals in terms of tumour
incidence, tumour growth rate or tumour weight at
the time of sacrifice (Table I). No metastases were
observed in this experiment, probably owing to the
short time which elapsed between the tumour graft
and the killing of the animals.
Chemically-induced intestinal tumours
Of the 60 DMH-treated animals, only 55 were
available for evaluation; 5 rats died in the course of
DMH gavage. The rats were sacrificed 7 months
after the first administration of DMH except for 4
animals: one was killed on account of a perforation
of the small intestine after 10 weeks of treatment by
indomethacin and cimetidine, 2 rats were killed
after 14 and 17 weeks of treatment with
indomethacin respectively for ascites and a tumour of
the ear duct, and one rat was killed forjaundice and
ascites after 25 weeks of treatment with cimetidine.
There was no significant difference in the weight
gain of the 4 experimental groups at the time of
Table I Effect of indomethacin, cimetidine and indomethacin +
cimetidine on transplanted colon carcinoma
Indomethacin
Control Indomethacin Cimetidine +cimetidine
No. of tumour-
bearing rats 13/14 15/15 13/15 14/14
Mean tumour
weight (s'd.) 7.11 7.55 6.40 5.76
per rat (1.27) (0.87) (1.36) (1.17)
Mean tumour
weight per
tumour-bearing 7.65 7.55 7.66 5.76
rats (s.d.) (1.24) (0.87) (1.35) (1.17)
s.d. =standard-deviation. No difference was statistically significant
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sacrifice. The number of intestinal tumours, their
extension and the number of tumour bearing
animals are reported in Table II. There was no
significant difference between controls and
indomethacin-treated animals. On the other hand,
the incidence of intestinal tumours, estimated by
comparison of the distribution of the tumours per
animal with Mann and Whitney's non parametric
test, was significantly higher in cimetidine-treated
rats than in control or indomethacin-treated
animals (P<0.05). There was also a tendency
toward more invasive and metastatic tumours in
the group tested with cimetidine. There was no
significant difference in the distribution of the
tumours along the intestine or in their histological
type. Of the 36 cancers observed in the 4 groups, 28
were well or moderately differentiated
adenocarcinomas, the other 8 being signet ring cells
or mucinous carcinomas. There was no difference
due to the treatment in the incidence of intestinal
neoplastic lesions classified as non-malignant
(adenomatous polyps or non invasive dysplasia), or
extra-intestinal tumours: liver haemangioendothelio-
sarcomas (2) or tumours of the external ear duct
(7). Small intestinal abrasions or ulcers were found
in 3 of the 14 indomethacin-treated rats. Two ulcers
of the small intestine, one complicated by
perforation, were observed in the animals treated
by cimetidine and indomethacin.
Discussion
The effect of cimetidine, a histamine type-2 receptor
antagonist, on the growth of experimental tumours
is controversial. Gifford et al. (1981) found that
cimetidine, given in the drinking water, improved
survival of mice injected i.p. with EL4 lymphoma
and suppressed the growth of Mc43 methylcholan-
threne-induced fibrosarcoma in syngeneic mice. He
suggested that cimetidine enhanced T-cell-mediated
cytotoxicity by inhibiting histamine-dependent
suppressor cells. Osband et al. (1981) also found
that cimetidine significantly slowed metastatic
development and prolonged survival in mice
injected with Lewis lung carcinoma. On the other
hand, Hannant et al. (1982), Ruitenberg et al.
(1982), Dorr et al. (1982), Collins & Hellmann
(1982) were unable to demonstrate any anti-tumour
activity of cimetidine in a variety of rat or mouse
tumours or leukaemias. Furthermore, Barna et al.
(1983) showed that cimetidine enhanced both
tumour size and extent of lung metastases of a
dibenzanthracene-induced fibrosarcoma growing in
syngeneic C57BL6 mice. Our own results are
another example of the inefficiency of cimetidine in
the control of experimental tumours. The results
obtained with dimethylhydrazine-induced primary
tumours further suggest, like the data of Barna et
al. (1983), an enhancing effect of cimetidine on
tumour growth. Cimetidine reduces gastric acid and
pepsin output. This could modify the systemic and
luminal environments of the intestine and thus
enhance the yield of dimethyldrazine-induced
carcinomas.
We found no effect of indomethacin treatment
on the growth of a transplanted intestinal
carcinoma nor on the incidence of intestinal
tumours induced by 1,2 dimethylhydrazine. These
negative results confirm our previous results where
indomethacin treatment did not modify the growth
of tumours induced in the rat by a subcutaneous
injection of syngeneic colon cancer cells (Olsson et
al., 1984). These results are contrary to the marked
inhibition of chemically-induced rat colon tumours
reported by others (Pollard & Luckert, 1980; 1981a,
Table II Effect of indomethacin, cimetidine and indomethacine+
cimetidine on intestinal carcinomas induced by dimethylhydrazine
Indomethacin
Control Indomethacin Cimetidine + Cimetidine
No. of tumour-
bearing rats 4/13 5/14 10/14 7/14
No. of rats with
metastatic
tumours (a) 0/13 3/14 4/14 1/14
No. of tumours:
- small intestine 0 2 4 2
- colon 6 4 12 6
- total 6 6 16 8
No. of tumours
invading the serosa 1 3 7 3
(a) number of rats with metastases to lung or lymph nodes or peritoneal
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1981b, 1983; Kudo et al., 1980; Narisawa et al.,
1981, 1982). The difference from the results
ontained by Pollard & Luckert (1980) in one of
their experiments is particularly striking since we
used the same strain of rats (Sprague-Dawley), the
same process for inducing intestinal tumours with
1-2 dimethylhydrazine and the same treatment by
the same dosage of indomethacin in drinking water.
In spite of these similarities, two major differences
were observed: first, the incidence of intestinal
tumours in the control animals was higher in
Pollard and Luckert's experiment than in our's
(respectively 29 tumour-bearing rats out of 29, with
a mean of 3.4 tumours per rat, versus 4 tumour-
bearing rats out of 13 with a mean of 0.46 tumours
per rat). The second was that indomethacin, which
significantly decreased the incidence of tumours and
the average number of tumours per rat in Pollard
and Luckert's experiment, was without effect on
these parameters in our experiment.
Dietary factors could explain the difference
between our results and data reported by other
groups. The incidence of intestinal tumours induced
in the rat by a variety of carcinogenic drugs
increases when animals are given a lipid-
supplemented diet (Reddy, 1983). Unsaturated fatty
acids are more efficient than saturated ones, chiefly
at low or intermediate concentrations. The same
enhancing effect of fatty acids is found for rat
mammary tumours, both spontaneous or chemically
induced (King et al., 1983). Carter et al. (1983)
have recently shown that indomethacin completely
blocked the stimulatory effect of a high-fat diet on
mammary tumours induced by diamethylbenzan-
thracene in Sprague-Dawley rats. Indomethacin had
no effect on mammary tumours induced with a low
incidence by this agent, in rats fed a low-fat diet.
Kollmorgen et al. (1983) have studied the effects of
indomethacin on the growth of a mammary tumour
transplanted in Wistar-Furth rats fed a semi-
purified diet containing 2, 5, 10 or 20% corn oil.
They found that the rate of tumour growth
increased with the dietary oil content in the
untreated animals. When the rats received
indomethacin in drinking water, at the same
concentration (20mg -1) as in our experiments, the
drug did not significantly reduce the slow tumour
growth in animals fed a low-fat diet. However, it
strongly reduced the growth of tumours
transplanted in rats fed high-fat diets. Kollmorgen
et al. (1983) also observed that high-fat diets
increased the concentration of prostaglandin PGE2
in supernatants of cultured spleen cells from
untreated animals. On the contrary, spleen cells of
rats treated by indomethacin produced only low
amounts of PGE2 whatever the oil content of their
diet.
In our experiments, rats were fed a diet
containing only 4.3% fatty acids of which 60%
were unsaturated. We have no details on the
composition of the commercial diets used by Kudo
et al. (1980) and Narisawa et al. (1981, 1982) in
their work on the inhibition of rat colon cancer by
indomethacin. Pollard and Luckert fed their rats
with a specific diet (Kellog & Wostmann, 1969)
which was probably rich in unsaturated fatty acids
since it contained 59% ground maize, 30% of
soybean oil meal and 3% corn oil. It is possible
that qualitative and quantitative differences in
dietary fats explain the difference between our
results and the data obtained by others in the
incidence of chemically-induced tumours and the
efficiency of indomethacin treatment in inhibiting
these tumours. If the data recently reported by
Carter et al. (1983) and Kollmorgen et al. (1983)
with the mammary tumour model may be
transported to colonic tumours, it might be
supposed that indomethacin is only active in
animals fed high-fat diets and able to synthesize
large amounts of prostaglandins whose inhibitory
effects on the immune system are well known
(Ceuppens and Goodwin, 1981). In another study,
using the same model, we found that indomethacin
was unable to modify tumour cell lysis by activated
macrophages from rats fed the same diet (Olsson et
al., 1984). It would be interesting to know if the
effects of indomethacin on colon cancer growth in
vivo and macrophage-mediated colon cancer cell
lysis in vitro are restored in animals fed a high-fat
diet.
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